Pharvaris to Present RAPIDe-3 Phase 3 HAE Data and CHAPTER-1 Results at AAAAI
Pharvaris will showcase six abstracts at AAAAI 2026 in Philadelphia Feb 27-Mar 2, featuring pivotal Phase 3 RAPIDe-3 data on oral deucrictibant for on-demand HAE treatment and final efficacy/safety results from Phase 2 CHAPTER-1. Three posters present PK findings for extended-release tablet ahead of CHAPTER-3 topline data due Q3.
1. Abstract Acceptance and Schedule
Pharvaris secured acceptance of six abstracts for poster presentation at the AAAAI 2026 Annual Meeting in Philadelphia from February 27 to March 2, including three featured posters in prime session slots. Presentations will cover both on-demand and prophylactic data for their oral bradykinin B2 receptor antagonist, deucrictibant.
2. Data Highlights
The program includes pivotal Phase 3 RAPIDe-3 results demonstrating on-demand efficacy and safety in hereditary angioedema (HAE) attacks, final efficacy and safety outcomes from the Phase 2 CHAPTER-1 open-label extension, pharmacokinetic data for the once-daily extended-release tablet, and validation of a novel kinin biomarker assay.
3. Upcoming Milestones
Investors and clinicians will gain early insight into the extended-release formulation ahead of topline CHAPTER-3 prophylaxis study results expected in the third quarter of 2026. Pharvaris is also advancing global marketing authorization applications for deucrictibant immediate- and extended-release formulations based on these findings.